SVRA
Savara Inc.
Healthcare — Biotechnology
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.
None
8 analysts
$5.05
$-0.11 (-2.23%)
Target:
$10.94
(116.8%)
Price History
52-Week Range
Sign in to add SVRA to a watchlist or set price alerts.
Fundamentals
| Market Cap | $1.25B |
| P/E Ratio (TTM) | - |
| Forward P/E | -20.78 |
| EPS (TTM) | $-0.56 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -79.95% |
| Debt/Equity | 17.11 |
| Recommendation | None |
| Analyst Target | $10.94 |
| Analysts | 8 |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 80.4 |
| Beta | 0.27 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $7.01 |
| 52-Week Low | $2.10 |
| 50-Day Avg | $5.28 |
| 200-Day Avg | $5.17 |
| Avg Volume | $1.75M |
| Volume | 281.6K |
Performance Analysis
NEUTRALSVRA presents a mixed picture with both positive and negative indicators.
~
Trading at 60% of its 52-week range.
-
RSI at 80.4 indicates overbought conditions — a pullback may be due.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
~
Wall Street consensus is "none" from 8 analysts.
+
Average analyst target of $10.94 implies 116.8% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:33 UTC
Back to Screener Export Report